Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Kontsekova

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Medical Hypotheses|February 1, 2011
Has prion protein important physiological function?Michal Prcina, Eva Kontsekova
Journal of Alzheimer'S Disease : JAD|June 23, 2011
Tauons and prions: infamous cousins?Petr Novak, Michal Prcina, Eva Kontsekova
Journal of Alzheimer'S Disease : JAD|October 28, 2008
Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathiesNorbert Zilka, Eva Kontsekova, Michal Novak
Protein and Peptide Letters|January 20, 2009
Structure solution of misfolded conformations adopted by intrinsically disordered Alzheimer's tau proteinJozef Sevcik, Rostislav Skrabana, Eva Kontsekova, et al.
Frontiers in Neuroscience|November 20, 2018
Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads AheadPetr Novak, Eva Kontsekova, Norbert Zilka, et al.
Cellular and Molecular Neurobiology|February 14, 2009
Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapyEva Kontsekova, Natalia Ivanovova, Martina Handzusova, et al.
Alzheimer'S Research & Therapy|December 6, 2014
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's diseaseEva Kontsekova, Norbert Zilka, Branislav Kovacech, et al.
Alzheimer'S Research & Therapy|December 6, 2014
First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease modelEva Kontsekova, Norbert Zilka, Branislav Kovacech, et al.
Biochemical Society Transactions|July 24, 2012
The self-perpetuating tau truncation circleNorbert Zilka, Branislav Kovacech, Peter Barath, et al.
Journal of Immunological Methods|August 21, 2008
High-yield purification of fetal tau preserving its structure and phosphorylation patternNatalia Ivanovova, Martina Handzusova, Jozef Hanes, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Medical Hypotheses|February 1, 2011
Has prion protein important physiological function?Michal Prcina, Eva Kontsekova
Journal of Alzheimer'S Disease : JAD|June 23, 2011
Tauons and prions: infamous cousins?Petr Novak, Michal Prcina, Eva Kontsekova
Journal of Alzheimer'S Disease : JAD|October 28, 2008
Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathiesNorbert Zilka, Eva Kontsekova, Michal Novak
Protein and Peptide Letters|January 20, 2009
Structure solution of misfolded conformations adopted by intrinsically disordered Alzheimer's tau proteinJozef Sevcik, Rostislav Skrabana, Eva Kontsekova, et al.
Frontiers in Neuroscience|November 20, 2018
Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads AheadPetr Novak, Eva Kontsekova, Norbert Zilka, et al.
Cellular and Molecular Neurobiology|February 14, 2009
Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapyEva Kontsekova, Natalia Ivanovova, Martina Handzusova, et al.
Alzheimer'S Research & Therapy|December 6, 2014
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's diseaseEva Kontsekova, Norbert Zilka, Branislav Kovacech, et al.
Alzheimer'S Research & Therapy|December 6, 2014
First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease modelEva Kontsekova, Norbert Zilka, Branislav Kovacech, et al.
Biochemical Society Transactions|July 24, 2012
The self-perpetuating tau truncation circleNorbert Zilka, Branislav Kovacech, Peter Barath, et al.
Journal of Immunological Methods|August 21, 2008
High-yield purification of fetal tau preserving its structure and phosphorylation patternNatalia Ivanovova, Martina Handzusova, Jozef Hanes, et al.
Pageof 3